Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Meta Expands AI Training With Employee Activity Tracking Tools 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SAN DIEGO and TORONTO, March 03, 2016 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the following upcoming conferences:
- Cowen & Company 36th Annual Healthcare Conference
Aptose’s corporate presentation is scheduled to take place at 2:00 p.m. ET on Monday, March 7, 2016 in Boston, MA. A corresponding live webcast of the presentation can be accessed by visiting:
- 28th Annual ROTH Conference
Aptose’s corporate presentation is scheduled to take place at 10:30 a.m. ET on Monday, March 14, 2016 in Dana Point, CA. A corresponding live webcast of the presentation can be accessed by visiting:
The audio webcasts will be archived shortly after the live event and will be available for 90 days through the Aptose website at www.aptose.com.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide additive or synergistic efficacy with existing anti-cancer therapies and regimens without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Greg Chow, CFO 647-479-9828 [email protected] BCC Partners Karen L. Bergman or Susan Pietropaolo 650-575-1509 or 845-638-6290 [email protected] or [email protected]
